NYSE: EBS
Emergent Biosolutions Inc Stock Forecast, Predictions & Price Target

Analyst price target for EBS

Based on 2 analysts offering 12 month price targets for Emergent Biosolutions Inc

Min Forecast
$12.00+159.74%
Avg Forecast
$13.50+192.21%
Max Forecast
$15.00+224.68%

Should I buy or sell EBS stock?

Based on 2 analysts offering ratings for Emergent Biosolutions Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although EBS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates EBS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their EBS stock forecasts and price targets.

EBS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-01
lockedlocked$00.00+00.00%2024-11-07

1 of 1

Forecast return on equity

Is EBS forecast to generate an efficient return?

Company
30.11%
Industry
30.59%
Market
76.12%
EBS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EBS forecast to generate an efficient return on assets?

Company
10.46%
Industry
12.74%
EBS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EBS earnings per share forecast

What is EBS's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
$1.20
Avg 2 year Forecast
$2.68

EBS revenue forecast

What is EBS's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$850.0M-18.55%
Avg 2 year Forecast
$1.1B+4.65%
EBS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EBS revenue growth forecast

How is EBS forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-18.55%
Industry
3.09%
Market
58.36%
EBS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EBS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EBS vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
EBS$4.62$13.50+192.21%Strong Buy
AQST$2.51$12.00+378.09%Strong Buy
ACB$4.44N/AN/A
LFCR$6.41$8.00+24.90%Buy
TKNO$5.76N/AN/A

Emergent Biosolutions Stock Forecast FAQ

Is Emergent Biosolutions Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSE: EBS) stock is to Strong Buy EBS stock.

Out of 2 analysts, 1 (50%) are recommending EBS as a Strong Buy, 1 (50%) are recommending EBS as a Buy, 0 (0%) are recommending EBS as a Hold, 0 (0%) are recommending EBS as a Sell, and 0 (0%) are recommending EBS as a Strong Sell.

If you're new to stock investing, here's how to buy Emergent Biosolutions stock.

What is EBS's earnings growth forecast for 2025-2026?

(NYSE: EBS) Emergent Biosolutions's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 79.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 70.58%.

Emergent Biosolutions's earnings in 2025 is -$190,600,000.On average, 2 Wall Street analysts forecast EBS's earnings for 2025 to be $64,932,746, with the lowest EBS earnings forecast at $17,387,848, and the highest EBS earnings forecast at $112,477,644.

In 2026, EBS is forecast to generate $145,351,545 in earnings, with the lowest earnings forecast at $82,592,280 and the highest earnings forecast at $208,110,810.

What is EBS's revenue growth forecast for 2025-2026?

(NYSE: EBS) Emergent Biosolutions's forecast annual revenue growth rate of -18.55% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3.09%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.36%.

Emergent Biosolutions's revenue in 2025 is $1,043,600,000.On average, 1 Wall Street analysts forecast EBS's revenue for 2025 to be $46,186,472,100, with the lowest EBS revenue forecast at $46,186,472,100, and the highest EBS revenue forecast at $46,186,472,100.

In 2026, EBS is forecast to generate $59,340,651,039 in revenue, with the lowest revenue forecast at $53,748,556,008 and the highest revenue forecast at $64,932,746,070.

What is EBS's forecast return on assets (ROA) for 2025-2026?

(NYSE: EBS) forecast ROA is 10.46%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 12.74%.

What is EBS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year EBS price target, the average EBS price target is $13.50, with the highest EBS stock price forecast at $15.00 and the lowest EBS stock price forecast at $12.00.

On average, Wall Street analysts predict that Emergent Biosolutions's share price could reach $13.50 by Apr 1, 2026. The average Emergent Biosolutions stock price prediction forecasts a potential upside of 192.21% from the current EBS share price of $4.62.

What is EBS's Earnings Per Share (EPS) forecast for 2025-2026?

(NYSE: EBS) Emergent Biosolutions's current Earnings Per Share (EPS) is -$3.60. On average, analysts forecast that EBS's EPS will be $1.20 for 2025, with the lowest EPS forecast at $0.32, and the highest EPS forecast at $2.07. In 2026, EBS's EPS is forecast to hit $2.68 (min: $1.52, max: $3.83).

What is EBS's forecast return on equity (ROE) for 2025-2026?

(NYSE: EBS) forecast ROE is 30.11%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.